Erasca, Inc. (ERAS) Cash Flow Statement

NASDAQ: ERASOperating cash, capex, free cash flow and buybacks.

Where ERAS’s cash came from and went, 2025

December 31, 2025 · U.S. dollars
Cash from operations
−$95.5M
Capital expenditures
$128,000
Free cash flow
−$95.6M
Returned to shareholders
—
Change in cash
$6.1M
cash at year-end $74.2M
Investments (net): $110.1MInvestments (net)$110.1MShare issuance (net): $724,000Share issuance (net)$724,000Cash used in operations: $95.5MCash used in operations$95.5M · 86%Acquisitions & other: $9.5MAcquisitions & other$9.5M · 9%Added to cash: $6.1MAdded to cash$6.1M · 5%Capital expenditures: $128,000Capital expenditures$128,000 · 0%$111.1M
Cash from operations
−$95.5M
Investments (net)
+$110.1M
Acquisitions & other
−$9.5M
Share buybacks (net)
+$724,000
Change in cash
$6.1M

Drawn to scale: where the cash came from and how it was used. Hover for values.

ERAS operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

ERAS cash flow trends, 2019–2025

Erasca, Inc. cash flow trends
MetricTrendThenLatestChange
Operating cash flow−$10.4M2019−$95.5M2025—
Capital expenditures$597,0002019$128,0002025−22.6%/yr
Free cash flow−$11.0M2019−$95.6M2025—
Stock-based compensation$122,0002019$24.9M2025+142.6%/yr
Share buybacks (net)$02021$02025—

Change is the average annual growth (CAGR) or the difference between the first and latest year.

ERAS cash flow by activity

OperatingInvestingFinancingChange in cash

ERAS net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

ERAS cash flow statement

Erasca, Inc. annual cash flow statement
2025202420232022202120202019
Operating activities
Net income−$124.5M−$161.7M−$125.0M−$242.8M−$122.8M−$101.7M−$12.0M
Depreciation & amortization$3.1M$3.8M$3.7M$2.6M$829,000$540,000$310,000
Stock-based compensation$24.9M$27.0M$26.2M$20.1M$8.3M$797,000$122,000
Change in working capital−$3.3M$1.7M$813,000$15.8M$7.7M$3.3M$1.7M
Other non-cash items$4.4M$19.7M−$7.0M$101.0M$26.3M$64.3M−$483,000
Cash from operating activities−$95.5M−$109.4M−$101.2M−$103.3M−$79.6M−$32.7M−$10.4M
Investing activities
Capital expenditures−$128,000−$22.6M−$1.8M−$16.6M−$18.9M−$38.7M−$597,000
Investments (net)$110.1M−$156.6M−$100.6M−$52.5M−$45.7M−$32.5M−$20.3M
Acquisitions & other investing−$9.5M$22.6M$11.2M−$2.0M$0$0$0
Cash from investing activities$100.4M−$156.6M−$91.2M−$71.1M−$64.6M−$71.2M−$20.9M
Financing activities
Share repurchases & issuance (net)$724,000$800,000$790,000$820,000$1.1M——
Shares issued$0$239.1M$0$95.3M$436.4M$137.0M$16.9M
Other financing$372,000$836,000$505,000$2.0M$1.9M$3.0M$0
Cash from financing activities$1.1M$240.7M$1.3M$98.1M$439.4M$140.0M$16.9M
Summary
Net change in cash$6.1M−$25.3M−$191.1M−$76.3M$295.2M$36.1M−$14.4M
Cash at end of period$74.2M$68.1M$93.5M$284.6M$360.9M$65.7M$29.6M
Free cash flow−$95.6M−$132.0M−$103.0M−$119.8M−$98.5M−$71.4M−$11.0M

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.

ERAS cash generation

In fiscal 2025 (ended December 31, 2025), Erasca generated -$95.5 million of cash from operations and spent $0.1 million on capital expenditures, leaving free cash flow of -$95.6 million. Cash and equivalents rose by $6.1 million over the year.

Related: ERAS income statement, ERAS balance sheet. See the ERAS stock overview for the latest quote and news.

ERAS cash flow FAQ

What is Erasca's free cash flow?

Erasca's free cash flow was -$95.6 million in fiscal 2025: -$95.5 million of operating cash flow minus $0.1 million of capital expenditures It was -$132.0 million a year earlier..

How much cash does Erasca generate from operations?

Erasca generated -$95.5 million of cash from operating activities in fiscal 2025.

How much does Erasca spend on capital expenditures?

Erasca spent $0.1 million on capital expenditures in fiscal 2025, compared with $22.6 million the year before.

Biotechnology: cash flow